Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Operating Leases of $39.0 million for Q1 2026, down 12.62% year-over-year from $44.6 million in Q1 2025, and down 3.82% quarter-over-quarter from $40.6 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $39.0 million for Q1 2026.
- In Q1 2026, Operating Leases fell 12.62% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (down 12.62% YoY), while the FY2025 annual figure was $40.6 million, down 3.53% from the prior year.
- Operating Leases for Q1 2026 stood at $39.0 million, down from $40.6 million in the prior quarter.
- The five-year high for Operating Leases was $55.5 million in Q1 2022, with the low at $39.0 million in Q1 2026.
- The 5-year median for Operating Leases is $47.8 million (2023), against an average of $47.3 million.
- The sharpest annual moves came in 2024 and 2025: Operating Leases slipped 15.97% in 2024, then rose 6.44% in 2025.
- Acadia Pharmaceuticals' Operating Leases stood at $52.7 million in 2022, then decreased by 9.29% to $47.8 million in 2023, then declined by 12.06% to $42.0 million in 2024, then decreased by 3.53% to $40.6 million in 2025, then slipped by 3.82% to $39.0 million in 2026.
- Business Quant data shows ACAD's Operating Leases at $39.0 million in Q1 2026, $40.6 million in Q4 2025, and $43.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.55 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Dec 31, 2025 | 40.55 Mn |
| Sep 30, 2025 | 43.03 Mn |
| Jun 30, 2025 | 44.60 Mn |
| Mar 31, 2025 | 44.63 Mn |
| Dec 31, 2024 | 42.04 Mn |
| Sep 30, 2024 | 40.42 Mn |
| Jun 30, 2024 | 47.19 Mn |
| Mar 31, 2024 | 49.19 Mn |
| Dec 31, 2023 | 47.80 Mn |
| Sep 30, 2023 | 48.10 Mn |
| Jun 30, 2023 | 49.78 Mn |
| Mar 31, 2023 | 51.44 Mn |
| Dec 31, 2022 | 52.70 Mn |
| Sep 30, 2022 | 53.77 Mn |
| Jun 30, 2022 | 54.69 Mn |
| Mar 31, 2022 | 55.48 Mn |
| Dec 31, 2021 | 56.13 Mn |
| Sep 30, 2021 | 57.68 Mn |